High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers

By afschroeder • August 9, 2025

Ennin E, Mallepally N, Ali M, Shojaie L, Dewberry S, Trieu M, Torres ETR, Zhou K, Kahn J, Dodge JL, Dara L. High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers. Liver Int. 2025 Sep;45(9):e70255. doi: 10.1111/liv.70255. PMID: 40778804.

Tags: CTLA‐4, Digestive Diseases, Fellow, ILICI, immune‐related adverse events, immunotherapy, liver injury, PD‐1, Publications

Decreased degree of adipocyte differentiation in visceral adipose tissue contributes to metabolic dysfunction-associated steatotic liver disease

Gelev KZ, Lee SHT, Alvarez M, Mancina RM, Tavaglione F, Jamialahmadi O, Vespasiani-Gentilucci U, Kar A, Wang Z, Kaminska D, Kaikkonen MU, Männistö V, Heinonen[...]

Summarization of Narrative Clinical Data of Inflammatory Bowel Disease With Foundational Large Language Models

Hong S, Greb AC, Shah-Riar P, Zheng HM, Limketkai BN. Summarization of Narrative Clinical Data of Inflammatory Bowel Disease With Foundational Large Language Models. Gastro[...]

Insurance Coverage for Endoscopic Bariatric Therapies in 2026: Analyses of Top Insurers in the US and Internal Validation

Garcia-Corella J, Shah S, Okafor C, Bechenati D, Arif Y, Bahdi F, Villarruel E, Larios K, Alhanaee M, Thaker A, Rosenthal RJ, Muthusamy VR, Issa[...]